Study of cervical cancer that spreads or returns in a few places
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at patients with cervical cancer that has spread to a few spots (oligo-metastasis) or come back in a limited area (oligo-recurrence). It aims to learn more about outcomes for these patients, especially those treated with radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has spread to a limited number of areas or come back in a limited area
- You may have had previous treatment, even if it was part of another study
- If your cancer spread to many areas, you must have had a good response to chemotherapy and then received radiation to the remaining spots
- You may have had other local treatments like surgery or ablation for the few spots
- You must have had follow-up care after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at women with cervical cancer that has spread to only a few places (oligo-metastatic) or come back in a few places (oligo-recurrent). It hopes to understand how well treating those spots with radiation or other local treatments works, even if you've already had treatment before.
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
This trial tests whether treating just the few spots where breast cancer has spread (called oligometastases) with radiation or surgery can help control the disease. It is for people whose cancer has spread to 3 or fewer places, each small in size, and who are healthy enough for local treatments.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This observational study follows people with rare solid tumors and a limited number of metastases treated with a focused radiation technique (SBRT). Doctors want to see outcomes after using a strong, curative-intent radiation dose to all active spots.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.